First Merchants Corp Sells 200 Shares of Edwards Lifesciences Corporation $EW

First Merchants Corp lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,840 shares of the medical research company’s stock after selling 200 shares during the period. First Merchants Corp’s holdings in Edwards Lifesciences were worth $222,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the company. Spectrum Asset Management Inc. NB CA boosted its holdings in shares of Edwards Lifesciences by 1.4% during the second quarter. Spectrum Asset Management Inc. NB CA now owns 39,083 shares of the medical research company’s stock worth $3,057,000 after acquiring an additional 540 shares during the period. Mirova US LLC boosted its holdings in shares of Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after acquiring an additional 1,054,301 shares during the period. BankPlus Trust Department boosted its holdings in shares of Edwards Lifesciences by 3.4% during the second quarter. BankPlus Trust Department now owns 11,907 shares of the medical research company’s stock worth $931,000 after acquiring an additional 391 shares during the period. Shell Asset Management Co. boosted its holdings in shares of Edwards Lifesciences by 45.1% during the second quarter. Shell Asset Management Co. now owns 61,172 shares of the medical research company’s stock worth $4,784,000 after acquiring an additional 19,014 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its holdings in shares of Edwards Lifesciences by 36.1% during the second quarter. KLP Kapitalforvaltning AS now owns 291,622 shares of the medical research company’s stock worth $22,808,000 after acquiring an additional 77,400 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $75.17 on Friday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The stock has a market cap of $44.13 billion, a price-to-earnings ratio of 10.82, a P/E/G ratio of 3.64 and a beta of 1.05. The company’s fifty day moving average is $78.20 and its 200 day moving average is $76.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $0.70 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of a number of research analyst reports. Piper Sandler boosted their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Barclays boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Morgan Stanley boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Finally, Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $87.06.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.